دورية أكاديمية
أعرض في EDS

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

التفاصيل البيبلوغرافية
العنوان: DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
المؤلفون: Michael Razavi, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong
المصدر: Military Medical Research, Vol 9, Iss 1, Pp 1-15 (2022)
بيانات النشر: BMC, 2022.
سنة النشر: 2022
المجموعة: LCC:Medicine (General)
LCC:Military Science
مصطلحات موضوعية: Glucagon-like peptide-1 receptor agonists, Dipeptidyl peptidase-4 inhibitors, Type 2 diabetes mellitus, Cardiovascular outcome, Medicine (General), R5-920, Military Science
الوصف: Abstract Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints. As a result, since 2008, the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety. The present review article strives to assess the safety and benefits of incretin-based therapy, a new class of antidiabetic drug, on the health of patient cardiovascular systems. In the process, this review will also provide a physiological overview of the incretin system and how key components function in T2DM.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2054-9369
العلاقة: https://doaj.org/toc/2054-9369Test
DOI: 10.1186/s40779-022-00410-2
الوصول الحر: https://doaj.org/article/d8f3f4f51e8f47c884d0ced18e16a237Test
رقم الانضمام: edsdoj.8f3f4f51e8f47c884d0ced18e16a237
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20549369
DOI:10.1186/s40779-022-00410-2